CWM
GILD icon

Catamount Wealth Management’s Gilead Sciences GILD Stock Holding History

Catamount Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-278
Closed -$23K – 162
2016
Q2 		$23K Hold
278
– – 0.03% 69
2016
Q1 		$26K Buy
278
+193
+227% +$17.4K 0.03% 65
2015
Q4 		$9K Hold
85
– – 0.01% 94
2015
Q3 		$8K Buy
+85
New +$9.44K 0.01% 96
2015
Q1 		– Sell
-26,989
Closed -$2.54M – 175
2014
Q4 		$2.54M Buy
+26,989
New +$2.79M 2.43% 16

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Catamount Wealth Management's GILD Position: Q3 2016 in Review

Catamount Wealth Management sold out of Gilead Sciences (GILD) in Q3 2016, closing a stake of 278 shares — an estimated $23K sold.

Catamount Wealth Management first reported a position in GILD in Q4 2014 and held it in 5 quarters. The position peaked at $2.54M in Q4 2014. 1,557 funds tracked by Wall St. Rank hold GILD as of Q3 2016.

  • Catamount Wealth Management reported no remaining Gilead Sciences position as of Q3 2016 after selling out during the quarter.
  • Catamount Wealth Management sold 278 Gilead Sciences shares in Q3 2016, an estimated $23K.
  • Catamount Wealth Management first reported a position in Gilead Sciences in Q4 2014 and held it in 5 quarters.
  • Catamount Wealth Management's Gilead Sciences position peaked at $2.54M in Q4 2014.
  • 1,557 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2016.

Based on Catamount Wealth Management's 13F filing for Q3 2016, filed 2 Nov 2016.